在中度至严重的坟墓的轨道病:一个随机,双盲,安慰剂控制,多中心研究Secukinumab.
Jan Wolf1, Katrin Lorenz2, Ahmed E Othman3
1Department of Medicine I, Johannes Gutenberg-University (JGU) Medical Center, Mainz 55101, Germany.
The Journal of clinical endocrinology and metabolism
|December 9, 2025
概括
一种IL-17A抑制剂Secukinumab在治疗活跃的Graves轨道病 (GO) 方面没有表现出有效性. 该研究发现,与GO患者的安慰剂相比,临床活性或亡没有显著改善.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
背景情况:
- 介质素17 (IL-17) 是一种促炎性细胞因子,涉及到Graves的轨道病变 (GO) 病原体.
- 升高的IL-17和Th17细胞与GO疾病活性和严重程度相关.
研究的目的:
- 评估一类IL-17A抑制剂secukinumab在患有活跃,中度至重度GO的患者中的疗效和安全性.
- 在ORBIT研究中,评估了secukinumab对GO的临床活性和的影响.
主要方法:
- 一个随机,双盲,安慰剂控制的多中心试验.
- 有活跃的,中度至重度GO的成年人接受了300毫克或安慰剂的sequukinumab皮下16周.
- 主要终点是通过降低的临床活性评分 (CAS) 和促来定义的整体反应.
主要成果:
- 招募了28名GO患者;在secukinumab或安慰剂组中,没有人获得整体反应.
- 在眼科症状,亡或生活质量方面没有观察到临床意义上的变化.
- 塞库金纽马布耐受性很好,但有轻微的不良反应,没有新的安全信号.
结论:
- 与安慰剂相比,secukinumab在患有活跃,中度至重度GO的患者中没有显示出临床疗效.
- 该研究表明,IL-17A抑制可能不是这种疾病的有效治疗策略.
相关概念视频
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:19Multiple Sclerosis l: Introduction
20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20